VIRTUAL KOL EVENT
The Potential Role of Anti-OX40/OX40L Monoclonal Antibodies (mAbs) in the Treatment of Alopecia Areata (AA)
Wednesday, May 28th, 2025 | 11:00AM ET
Designed to be different:
Developing a potential best-in-class anti-OX40 treatment with features that matter to patients
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases. IMG-007 is our next-generation investigational anti-OX40 monoclonal antibody.
IMG-007
IMG-007 is an extended half-life anti-OX40 monoclonal antibody in clinical development that targets and inhibits OX40 receptor signaling without depleting T cells for potential enhanced efficacy, safety, and patient convenience.
News
March 10, 2026
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
read more »February 10, 2026